Akston Biosciences
Beverly, US · Delaware corporation · 2 known investors
Akston Biosciences develops protein-based therapies for pets to support veterinary care and improve treatment accessibility. The company focuses on pet-focused biotechnology aimed at making animal therapies more affordable for pet owners.
BiotechHealthtech
Founders & leadership
TC
Todd C. ZionFounder
JH
James HerrimanNamed on SEC filing
RD
Robyn DavisNamed on SEC filing
LE
Lovick E. CannonNamed on SEC filing
TM
Thomas M. LancasterNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.7M disclosed across 5 rounds · 2019–2022
▶$5.2MraisedApr 2022 · 37 investors · BiotechnologyRule 506(b)
▶$5.2MraisedApr 2022 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HerrimanExecutive Officer
- Thomas M. LancasterExecutive Officer, Director
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Robyn DavisDirector
- Offering amount
- $10M
- Amount sold
- $5.2M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.9MraisedJun 2021 · 71 investors · BiotechnologyRule 506(b)
▶$7.9MraisedJun 2021 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Thomas M. LancasterExecutive Officer, Director
- James HerrimanExecutive Officer
- Robyn DavisDirector
- Offering amount
- $8M
- Amount sold
- $7.9M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJun 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HerrimanExecutive Officer
- Robyn DavisDirector
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Thomas M. LancasterExecutive Officer, Director
- Offering amount
- $11.8M
- Amount sold
- $1M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedMay 2020 · 71 investors · BiotechnologyRule 506(b)
▶$5.1MraisedMay 2020 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HerrimanExecutive Officer
- Thomas M. LancasterExecutive Officer, Director
- Todd C. ZionExecutive Officer, Director
- Lovick E. CannonDirector
- Robyn DavisDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJun 2019 · 46 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2019 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robyn DavisDirector
- James HerrimanExecutive Officer
- Thomas M. LancasterExecutive Officer, Director
- Lovick E. CannonDirector
- Todd C. ZionExecutive Officer, Director
- Offering amount
- $2.8M
- Amount sold
- $2.5M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCBS News6 shared keywordsCBS News is a news organization publishing reporting and video coverage on U.S. and world politics, business, science, health, and entertainment, including its free CBS News 24/7 streaming service.
Fox News5 shared keywordsFOX News Media is a news and media organization that produces news reporting, opinion, and analysis across cable television, digital, audio, books, and streaming services. Its platforms include cable news and business networks, digital and audio operations, and direct-to-consumer and ad-supported streaming services.
Companies competing with Akston Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $249.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $249.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Akston Biosciences do?
- Akston Biosciences develops protein-based therapies for pets to support veterinary care and improve treatment accessibility. The company focuses on pet-focused biotechnology aimed at making animal therapies more affordable for pet owners.
- Who founded Akston Biosciences?
- Akston Biosciences was founded by Todd C. Zion.
- Who are Akston Biosciences's investors?
- Akston Biosciences's investors include Boston Harbor Angels, Formation Venture Engineering.
- How much funding has Akston Biosciences raised?
- Akston Biosciences has disclosed $21.7M raised across 5 rounds.
- Where is Akston Biosciences headquartered?
- Akston Biosciences is headquartered in Beverly, US.